Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2025-01-28 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model
Regulatory Filings Classification · 95% confidence The document is a press release dated January 28, 2025, announcing early encouraging data from a collaboration between EXACT Therapeutics and Cordance Medical regarding brain cancer treatment in mice models. It details scientific findings, quotes CEOs, and provides company descriptions. This type of announcement, which is a general corporate update about scientific progress or partnership results, does not fit neatly into specific financial reporting categories like 10-K, ER, or IR. It is a general corporate communication. Since it is not a formal regulatory filing (like a 10-K or 8-K), nor a specific report (like an AR or IR), nor a presentation (IP), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a broad communication to the market about company developments.
2025-01-28 English
EXACT Therapeutics initiates preclinical immunotherapy collaboration with Agenus Inc.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a preclinical research collaboration between EXACT Therapeutics and Agenus Inc. regarding immunotherapy and drug delivery technology. This type of announcement, detailing strategic partnerships, research milestones, or business developments that do not fit into specific financial reporting categories (like 10-K, ER, or DIV), typically falls under general regulatory announcements or investor relations news. Since it is not a formal financial report (like 10-K or IR), nor a specific event announcement (like AGM or DIV), and it is a formal communication to the market, the most appropriate general category is Regulatory Filings (RNS), which serves as a catch-all for significant, non-standard corporate news releases. The length (4135 chars) is substantial enough to be the primary document, not just a brief announcement of a report (which would suggest RPA).
2024-10-08 English
EXACT Therapeutics to Present at the bi-annual Contrast Media Research (CMR) Symposium 2024
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that EXACT Therapeutics will be presenting at the Contrast Media Research (CMR) Symposium 2024. It details the presentation title, time, and location, and mentions that the presentation will be made available on the company's website. Since the document itself is an announcement about an upcoming event/presentation rather than the presentation material itself, and it doesn't fit the specific criteria for ER, IR, or CT, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) announcement. Given the context of a symposium presentation announcement, RNS (Regulatory Filings/General Announcement) is the most appropriate general category, as it is not the full Investor Presentation (IP) document itself, nor is it a financial results release (ER). The length is short (3136 chars), supporting the idea that it is an announcement rather than a full report.
2024-10-02 English
EXACT Therapeutics announces first half 2024 interim results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FIRST HALF REPORT 2024' and contains comprehensive financial statements (Consolidated statement of comprehensive income, cash flow, financial position) for the six-month period ended 30 June 2024. It includes a management review, risk assessment, and a responsibility statement from the Board of Directors. It is clearly an interim financial report rather than an announcement or a full annual report. H1 2024
2024-09-30 English
EXACT Therapeutics announces first half 2024 interim results
Earnings Release Classification · 100% confidence The document explicitly states it is announcing the 'interim results for the first half 2024'. This points towards a periodic financial report shorter than a full year, matching the definition of an Interim / Quarterly Report (IR). However, the text is very short (2632 chars) and primarily serves as an announcement, stating: 'The interim report and presentation for the first half year 2024 are also available on the company's website'. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement pointing to the full report suggests a Report Publication Announcement (RPA). Since the core content is the release of the 'interim results' document, and RPA is defined as an announcement regarding the publication of reports, RPA is the most precise classification based on the document's structure and length, even though the subject matter relates to an Interim Report (IR). H1 2024
2024-09-30 English
EXACT Therapeutics announces grant of immunotherapy patent
Regulatory Filings Classification · 100% confidence The document is a press release announcing that EXACT Therapeutics has been granted a specific patent (UK Patent No: 2 605 996) related to its Acoustic Cluster Therapy (ACT®) in combination with immunotherapy. This announcement concerns intellectual property rights and is not a standard financial report (like 10-K, IR, or ER). Among the provided categories, 'Legal Proceedings Report (LTR)' covers significant lawsuits or regulatory actions, but patent grants are generally classified under broader regulatory or informational announcements. Since the core subject is the granting of an Intellectual Property right, and there isn't a specific 'IP Grant' code, this falls best under 'Regulatory Filings (RNS)' as a general regulatory/official announcement that doesn't fit the other specific financial or corporate action codes. The document length is short (2860 chars), but it is the primary announcement itself, not an announcement *of* another report, so RPA is not appropriate. It is a specific corporate event announcement.
2024-09-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.